Komori
Seed (7743) · InitiativeAdvanced

Preparation for clinical trials of drug-releasing soft contact lenses

First written in FY2016. 2 of 4 entries say "Advanced", first in FY2019. Latest entry: FY2025.

4entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016AdvancedFY2019 – FY20252016: 120162017: 020172018: 020182019: 120192020: 020202021: 020212022: 120222023: 020232024: 020242025: 12025
Same theme, other companies
Clinical trials and collaborative research for drug-releasing soft contact lensesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025AdvancedAnnual report

    「The company is proceeding with clinical trials for soft contact lenses that continuously release medication. It is also pursuing joint research and development with universities and pharmaceutical manufacturers on combination drug-device products for intractable diseases.」

    The company is continuing clinical trials for drug-release control soft contact lenses and joint research on combination drug-device products for intractable diseases.
  2. FY2022AchievedAnnual report

    「For soft contact lenses that continuously release medication, the company has completed the selection of target diseases and drugs and begun clinical trials.」

    The company has moved from preparing for clinical trials and consulting with regulatory authorities to the stage of conducting clinical trials.
  3. FY2019AdvancedAnnual report

    「For soft contact lenses that continuously release medication, the company has completed the selection of target diseases and drugs and is conducting discussions with regulatory authorities and the various tests required for the application, with a view to obtaining approval at an early stage.」

    Following completion of the selection of diseases and drugs, the company has advanced to the stage of consulting with regulatory authorities and conducting the tests required for an application, with a view to obtaining approval at an early stage.
  4. FY2016First statedAnnual report

    「For soft contact lenses incorporating drug-release control, or DDS (drug delivery system), the company has completed the selection of target diseases and drugs and is consulting with the relevant parties to conduct clinical trials at an early stage through a collaborative framework with universities and pharmaceutical manufacturers.」

    The company has completed the selection of diseases and drugs and is pursuing discussions toward clinical trials through a collaborative framework with universities and pharmaceutical manufacturers.
Moved together

"Strengthening the Sales Strategy" moved the same way as this thread, in the same document, in 3 of its 4 moves.

333333★123456
  1. ★This thread
  2. 1Strengthening the Sales Strategy3×
  3. 2Strengthening Production and Development Capabilities3×
  4. 3Overseas Business Expansion and Sales Channel Development3×
  5. 4Expansion of production capacity and capabilities for new materials through the new building at the Konosu Research Institute3×
  6. 5Growth through increasing domestic market share and developing overseas sales channels3×
  7. 6Development of High-Performance Contact Lenses and Medical and Pharmaceutical Products3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Seed yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Preparation for clinical trials of drug-releasing soft contact lenses | SEED CO.,LTD. (7743) | Komori